Efficacy and Safety of Necitumumab and Pembrolizumab Combination Therapy in Stage IV Nonsquamous Non-Small Cell Lung Cancer (NSCLC)

被引：4

作者：

Besse, Benjamin ^{[1
]}

Garrido, Pilar ^{[2
]}

Puente, Javier ^{[3
]}

Cortot, Alexis ^{[4
]}

Eugenia Olmedo, Maria ^{[2
]}

Perol, Maurice ^{[5
]}

Gil, Maciej ^{[6
]}

Chao, Grace ^{[7
]}

Shahidi, Javad ^{[8
]}

Bennouna, Jaafar ^{[9
]}

机构：

[1] Gustave Roussy, Dept Canc Med, Villejuif, France

[2] Hosp Univ Ramon Y Cajal, Med Oncol Dept, Madrid, Spain

[3] Hosp Clin San Carlos, Med Oncol Dept, Madrid, Spain

[4] Lille Univ Hosp, Thorac Oncol, Lille, France

[5] Ctr Leon Berard, Grp Thorac & Orl, Lyon, France

[6] Eli Lilly, Warsaw, Poland

[7] Eli Lilly & Co, Bridgewater, MA USA

[8] Eli Lilly & Co Bridgewater, Bridgewater, MA USA

[9] Inst Cancerol LOuest, Nantes, France

来源：

关键词：

non-small cell lung cancer; Necitumumab; pembrolizumab;

D O I：

10.1016/j.jtho.2016.11.451

中图分类号：

R73 [肿瘤学];

学科分类号：

100214 ;

摘要：

MA09.11

引用

页码：S397 / S397

页数：1